Skip to main content

Table 2 Correlation coefficients between the staging systems vs. the PFT parameters (FVC and DLCO at baseline and after 12 months of treatment)

From: Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

Staging systems FVC (baseline) FVC (absolute change) DLCO (baseline) DLCO (absolute change)
Placebo CYC Placebo CYC Placebo CYC Placebo CYC
MaxFib −0.21 (0.15) −0.16 (0.29) −0.31 (0.88) 0.34 (0.02) −0.46 (0.001) −0.44 (0.003) −0.02 (0.88) 0.13 (0.41)
Goh and Wells unadjusted stratification −0.05 (0.75) −0.25 (0.09) −0.21 (0.15) 0.10 (0.50) −0.48 (0.001) −0.51 (0.001) 0.003 (0.98) 0.17 (0.27)
QILD WL −0.38 (0.008) −0.08 (0.61) −0.23 (0.12) 0.41 (0.006) −0.35 (0.01) −0.07 (0.63) −0.35 (0.02) 0.12 (0.45)
QILD ZM −0.27 (0.07) −0.19 (0.23) −0.20 (0.17) 0.40 (0.008) −0.41 (0.005) −0.24 (0.12) −0.30 (0.04) 0.25 (0.10)
QLF WL −0.17 (0.26) −0.25 (0.11) −0.22 (0.13) 0.06 (0.62) −0.22 (0.13) −0.20 (0.20) −0.10 (0.50) 0.16 (0.32)
QLF ZM −0.45 (0.002) −0.39 (0.02) −0.15 (0.31) 0.18 (0.23) −0.43 (0.002) −0.41 (0.005) −0.22 (0.13) 0.12 (0.45)
  1. FVC forced vital capacity, MaxFib visual maximum fibrosis score, QILD WL quantitative assessment of total extent of interstitial lung disease in whole lung, QILD ZM quantitative assessment of total extent of interstitial lung disease in zone of maximal involvement, QLF WL quantitative percentage with fibrosis in whole lung, QLF ZM quantitative percentage with fibrosis in zone of maximal involvement, CYC cyclophosphamide, DLCO diffusing capacity for carbon monoxide
  2. The values are Pearson’s correlation coefficients; p values are presented in parentheses